Reported Thursday, Sep 24 - 11:07am EDT (TheFly subscription required to read more.)

Reported Thursday, Sep 24 - 7:04am EDT (TheFly subscription required to read more.)

A clinical-stage cell therapy company building CAR-T cells you can switch off and on - even after they are inside the patient.

AvenCell Therapeutics presented updated results for its CAR-T cell blood cancer therapy at EHA 2026.

AvenCell Therapeutics reveals pivotal Phase 1a results for its innovative switchable CAR-T therapy targeting acute myeloid leukemia at the upcoming EHA 2026.

AvenCell Therapeutics has initiated its Phase I QUADvance study for AVC-203, a CAR-T therapy targeting B-cell malignancies, marking a significant milestone.

AvenCell Therapeutics has received both FDA's IND clearance and EMA's approval for the QUADvance clinical trial, advancing its promising therapy for B-cell malignancies.

AvenCell Japan has been awarded a significant grant to advance its innovative allogeneic CAR-T therapies, addressing critical unmet needs in cancer treatment.

AVC-203 is the world's first CRISPR-engineered allogeneic dual-targeting CD19/CD20 switchable CAR-T cell therapy to enter clinical testing WATERTOWN, Mass., April 2, 2026 /PRNewswire/ -- AvenCell Therapeutics, Inc., a leading clinical-stage cell therapy company focused on advancing both...

CAMBRIDGE, Mass., Dec. 4, 2025 /PRNewswire/ -- AvenCell Therapeutics, Inc., a leading clinical-stage cell therapy company focused on advancing both switchable and allogeneic CAR-T cell therapies, today announced that the FDA and the European Medicines Agency (EMA) have cleared the...

TOKYO, June 30, 2025 /PRNewswire/ -- AvenCell Japan, a wholly owned subsidiary of AvenCell Therapeutics, a private, clinical-stage biotechnology company developing best-in-class CAR-T therapies for hematologic cancers and autoimmune diseases, today announced it has been awarded a grant of...

AvenCell Therapeutics announced that it raised $115 million in a Series B round. The company is developing CAR-T therapies that can be turned “on” or “off” with a goal to…

AvenCell selected ViroCell for retroviral vector CDMO services to drive its pipeline of innovative allogeneic CAR T-cell therapies, based on ViroCell’s deep expertise and track record. LONDON & NEW YORK–(BUSINESS WIRE)–ViroCell Biologics (“ViroCell”), a specialist viral vector Contract Development and Manufacturing Organisation (“CDMO”) for cell and gene therapy (CGT) clinical trials, announces a manufacturing collaboration …

ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers  Business Wire

Plus, news about Bayer, Tempus AI, Apellis, Sobi, Nektar Therapeutics, Cybin, atai Life Sciences, HanchorBio, Henlius, Portal Biotech, Roche, AvenCell Therapeutics, Adagene and BerGenBio: Broad Institute lays off staff, cuts costs: The Harvard-MIT research center ...